Stocktoria
Xeris Biopharma Holdings, Inc. XERS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Xeris Biopharma Holdings, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $20.4M |
| R&D expense | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M | $20.9M |
| SG&A expense | $182.4M | $163.5M | $146.1M | $137.7M | $125.7M | $73.7M |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M | -$83.5M |
| Interest expense | — | — | $26.6M | $14.1M | $7.2M | $10.7M |
| Income tax | $0 | -$2.3M | -$1.2M | -$1.4M | $0 | -$110,000 |
| Net income | $554,000 | -$54.8M | -$62.3M | -$94.7M | -$122.7M | -$91.1M |
| EPS (diluted) | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | — |
| Operating cash flow | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M | -$80.6M |
| Free cash flow | — | — | — | — | -$96.6M | -$80.9M |
| Cash & equivalents | $111.0M | $71.6M | $67.4M | $122.0M | $67.3M | $37.6M |
| Inventory | $68.7M | $48.2M | $38.8M | $24.7M | $18.1M | $8.4M |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M | $159.2M |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M | $125.4M |
| Shareholders' equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M | $33.8M |
Growth · year-over-year · Revenue CAGR 70.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +43.7% | +23.9% | +48.7% | +122.3% | +142.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.